After reporting on the FDA Advisory Committee meeting for Biogen’s phase 3 trial drug aducanumab, Phil started wrestling with two parts of himself: should the guy who believes in science prevail, or the guy living with the diagnosis?
This week, picking up where we left off in Episode 143: “We have a friend,” Christy throws in her emotional thinking on the topic.
Toward the end, Christy urges voters to think about how elected officials vote on funding research at NIH and what that means:
On December 17, 2019, the House passed H.R. 1865, the Further Consolidated Appropriations Act, 2020, by a vote of 297-120. On December 19, 2019, the Senate passed H.R. 1865 by a vote of 71-23….
Of note, the bill provides $41.7 billion for medical research at the NIH, a nearly seven percent increase over FY 2019 funding. This funding for the NIH includes an extra $350 million for Alzheimer’s disease and related dementias (AD/ADRD) research, bringing the NIH’s total AD/ADRD funding to $2.8 billion. (Source: September 2020 Director’s Status Report)
$2.8 bn is a huge chunk of change. For context, though, “the FY 2020 Department of Health and Human Services Appropriations Act and the 21st Century Cures Act allocated $6.44 billion to NCI (National Cancer Institute), a $297 million net increase over the FY 2019 enacted regular and Cancer Moonshot appropriations.” (Source: NIH/NCI)
- Phil’s Journal: Reflections on Alzheimer’s Drug Aducanumab’s Latest Snag
- 5 takeaways from the FDA’s high-stakes meeting for Biogen’s Alzheimer’s drug
- The Most Promising Alzheimer’s Drug in Years Took a Thrashing From an FDA Advisory Committee
- 2021 Monthly + Daily Planner for Dementia Care Partners with Pro Tips from The Dementia Sherpa
Mike Good founded The Alzheimer’s Podcast in May 2017. Christy appears as a guest in episodes 15, 19, 21, and 23-26. She became the featured expert on the show starting with episode 28 and appears in every episode after, except 56. When Mike decided to follow his bliss, Christy took over the show in January 2019.
If you have questions or comments for Phil (or me), please let us know! We love hearing from you 🙂